310 related articles for article (PubMed ID: 21403904)
1. Laboratory animal models for brucellosis research.
Silva TM; Costa EA; Paixão TA; Tsolis RM; Santos RL
J Biomed Biotechnol; 2011; 2011():518323. PubMed ID: 21403904
[TBL] [Abstract][Full Text] [Related]
2. Towards a Brucella vaccine for humans.
Perkins SD; Smither SJ; Atkins HS
FEMS Microbiol Rev; 2010 May; 34(3):379-94. PubMed ID: 20180858
[TBL] [Abstract][Full Text] [Related]
3. The NOD-
Khalaf OH; Chaki SP; Garcia-Gonzalez DG; Ficht TA; Arenas-Gamboa AM
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936160
[TBL] [Abstract][Full Text] [Related]
4. Research progress in live attenuated Brucella vaccine development.
Wang Z; Wu Q
Curr Pharm Biotechnol; 2013; 14(10):887-96. PubMed ID: 24372253
[TBL] [Abstract][Full Text] [Related]
5. The advances in brucellosis vaccines.
Hou H; Liu X; Peng Q
Vaccine; 2019 Jul; 37(30):3981-3988. PubMed ID: 31176541
[TBL] [Abstract][Full Text] [Related]
6. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans.
Ko J; Splitter GA
Clin Microbiol Rev; 2003 Jan; 16(1):65-78. PubMed ID: 12525425
[TBL] [Abstract][Full Text] [Related]
7. Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.
Bundle DR; McGiven J
Acc Chem Res; 2017 Dec; 50(12):2958-2967. PubMed ID: 29219305
[TBL] [Abstract][Full Text] [Related]
8. Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.
Moustafa D; Garg VK; Jain N; Sriranganathan N; Vemulapalli R
Vaccine; 2011 Jan; 29(4):784-94. PubMed ID: 21109033
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide as a target for brucellosis vaccine design.
Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
[TBL] [Abstract][Full Text] [Related]
10. Development and trial of vaccines against
Lalsiamthara J; Lee JH
J Vet Sci; 2017 Aug; 18(S1):281-290. PubMed ID: 28859268
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic and protective antigens of Brucella as vaccine candidates.
Masjedian Jezi F; Razavi S; Mirnejad R; Zamani K
Comp Immunol Microbiol Infect Dis; 2019 Aug; 65():29-36. PubMed ID: 31300122
[TBL] [Abstract][Full Text] [Related]
12. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model.
Bugybayeva D; Kydyrbayev Z; Zinina N; Assanzhanova N; Yespembetov B; Kozhamkulov Y; Zakarya K; Ryskeldinova S; Tabynov K
Infect Dis Poverty; 2021 Feb; 10(1):13. PubMed ID: 33593447
[TBL] [Abstract][Full Text] [Related]
13. Brucella: a Mr "Hide" converted into Dr Jekyll.
Gorvel JP
Microbes Infect; 2008 Jul; 10(9):1010-3. PubMed ID: 18664389
[TBL] [Abstract][Full Text] [Related]
14. Partial protection induced by Salmonella based Brucella vaccine candidate in pregnant guinea pigs.
Lalsiamthara J; Senevirathne A; Lee JH
Vaccine; 2019 Feb; 37(7):899-902. PubMed ID: 30661832
[TBL] [Abstract][Full Text] [Related]
15. Selection of a Brucella vaccine strain of low residual virulence by chemical mutagenesis.
Zhao WR; Wendoso ; Hasi ; Qin YX; Weng W; Lu SL
J Med Microbiol; 1989 Oct; 30(2):143-8. PubMed ID: 2795638
[TBL] [Abstract][Full Text] [Related]
16. Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing
Bugybayeva D; Ryskeldinova S; Zinina N; Sarmykova M; Assanzhanova N; Kydyrbayev Z; Tabynov K
Biomed Res Int; 2020; 2020():1438928. PubMed ID: 33274194
[TBL] [Abstract][Full Text] [Related]
17. Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.
Arenas-Gamboa AM; Rice-Ficht AC; Fan Y; Kahl-McDonagh MM; Ficht TA
Clin Vaccine Immunol; 2012 Feb; 19(2):249-60. PubMed ID: 22169089
[TBL] [Abstract][Full Text] [Related]
18. What have we learned from brucellosis in the mouse model?
Grilló MJ; Blasco JM; Gorvel JP; Moriyón I; Moreno E
Vet Res; 2012 Apr; 43(1):29. PubMed ID: 22500859
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
[TBL] [Abstract][Full Text] [Related]
20. Rough brucella strain RM57 is attenuated and confers protection against Brucella melitensis.
Feng Y; Peng X; Jiang H; Peng Y; Zhu L; Ding J
Microb Pathog; 2017 Jun; 107():270-275. PubMed ID: 28390976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
